Trials / Completed
CompletedNCT01435096
BN80927 in Patients With Advanced Malignant Solid Tumors
A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BN80927 | Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment. |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2011-09-15
- Last updated
- 2020-03-03
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01435096. Inclusion in this directory is not an endorsement.